[{"info":{"CSQN":"Missense","candidate_mnv_variants":"chr7:g.116417452_116417453delGTinsTA,chr7:g.116417452_116417453delGTinsTC,chr7:g.116417452_116417453delGTinsTG","aliases":"NP_001120972","reference_codon":"GGT","dbxref":"GeneID:4233,HGNC:7029,MIM:164860","candidate_codons":"GTA,GTC,GTG,GTT","source":"RefSeq"},"region":"inside_[cds_in_exon_16]","strand":"+","alt_allele":"T","coordinates":{"cell":[],"DNA":"chr7:g.116417452G>T","cDNA":"c.3323G>T","mtct":[["overlap","1499","Anti-EGFR mAbs","MET","Amplification","Reduced sensitivity or response","Clinical trial stage","Colorectal cancer","23729478","116312443","116438440"],["overlap","1254","BCL2 inhibitors","MET","Amplification","Increased sensitivity or response","Preclinical stage","Colorectal cancer","27397505","116312443","116438440"],["overlap","2511","Cabozantinib + panitumumab","MET","Amplification","Increased sensitivity or response","Case report stage","Colorectal cancer","ENA 2015 (abstract A52)","116312443","116438440"],["overlap","848","Crizotinib","MET","Amplification","Increased sensitivity or response","Clinical trial stage","Lung adenocarcinoma","ASCO 2014 (abstr 8001), ASCO 2015 (abstr 2595)","116312443","116438440"],["overlap","2232","Crizotinib","MET","AMPLIFICATION","Increased sensitivity or response","Case report stage","Lung adenocarcinoma","26724472, 25922291","116312459","116436396"],["overlap","1778","Crizotinib","MET","AMPLIFICATION","Increased sensitivity or response","Preclinical stage","Non-small cell lung carcinoma","21716144","116312459","116436396"],["overlap","1483","Crizotinib","MET","AMPLIFICATION","Increased sensitivity or response","Case report stage","Glioblastoma multiforme","22162573","116312459","116436396"],["overlap","563","Crizotinib","MET","AMPLIFICATION","Increased sensitivity or response","Case report stage","Lung squamous cell carcinoma","24192513","116312459","116436396"],["overlap","4569","Crizotinib","MET","Amplification","Increased sensitivity or response","Clinical trial stage","Lung cancer","http://meetinglibrary.asco.org/content/132030-144","116312443","116438440"],["overlap","3044","Crizotinib","MET","C.3028G>A exon 14 splicing variant","Increased sensitivity or response","Case report stage","Lung cancer","26729443","116312443","116438440"],["overlap","3811","Crizotinib","MET","AMPLIFICATION","Increased sensitivity or response","Case report stage","Colorectal cancer","27325282","116312459","116436396"],["overlap","2403","Crizotinib","MET","EXON 14 MUTATION + AMPLIFICATION","Increased sensitivity or response","Case report stage","Non-small cell lung carcinoma","26729443","116312459","116436396"],["overlap","3551","Crizotinib","MET","Fusion gene","Increased sensitivity or response","Case report stage","Malignant glioma","27748748","116312443","116438440"],["overlap","2735","Crizotinib","MET","Amplification","Increased sensitivity or response","Case report stage","Malignant glioma","22162573","116312443","116438440"],["overlap","302","Crizotinib","MET","OVEREXPRESSION","Increased sensitivity or response","Preclinical stage","Uveal melanoma","24140933","116312459","116436396"],["overlap","4007","Crizotinib","MET","AMPLIFICATION","Increased sensitivity or response","Case report stage","Cancer","25232318","116312459","116436396"],["overlap","3878","Crizotinib","MET","AMPLIFICATION","Increased sensitivity or response","Case report stage","Non-small cell lung carcinoma","21623265, 27664533","116312459","116436396"],["overlap","675","Crizotinib","MET","Exon 16-19 p.1132-1330","Increased sensitivity or response","Clinical trial stage","Kidney cancer","AACR 2016 (abstr CT2006)","116417443","116417523"],["overlap","3258","Crizotinib + trastuzumab (in HER2 co-amplified)","MET","Amplification","Increased sensitivity or response","Case report stage","Stomach cancer","26432108","116312443","116438440"],["overlap","3257","Crizotinib and vemurafenib (in BRAF V600E mutated)","MET","Amplification","Increased sensitivity or response","Case report stage","Colorectal cancer","27325282","116312443","116438440"],["overlap","4383","EGFR TKIs (EGFR mut disease)","MET","Amplification","Reduced sensitivity or response","Clinical trial stage","Lung adenocarcinoma","ASCO 2015 (abstr 8089)","116312443","116438440"],["overlap","4552","Erlotinib","MET","AMPLIFICATION","Reduced sensitivity or response","Case report stage","Lung adenocarcinoma","23470965","116312459","116436396"],["overlap","4426","Foretinib","MET","MUTATION","Increased sensitivity or response","Clinical trial stage","Papillary renal cell carcinoma","23213094","116312459","116436396"],["overlap","1473","Gefitinib","MET","AMPLIFICATION","Reduced sensitivity or response","Preclinical stage","Non-small cell lung carcinoma","17463250","116312459","116436396"],["overlap","1297","Gefitinib","MET","AMPLIFICATION","Reduced sensitivity or response","Case report stage","Lung adenocarcinoma","23470965","116312459","116436396"],["overlap","2847","Lapatinib in HER2-amplified","MET","Amplification","Reduced sensitivity or response","Preclinical stage","Stomach cancer","22238368","116312443","116438440"],["overlap","874","MET inhibitors","MET","Amplification","Increased sensitivity or response","Clinical trial stage","Kidney cancer","23213094, AACR 2016 (abstr CT2006)","116312443","116438440"],["overlap","2898","MET inhibitors","MET","Amplification","Increased sensitivity or response","Clinical trial stage","Stomach cancer","ASCO GI 2015 (abstr 1)","116312443","116438440"],["overlap","810","MET inhibitors","MET","Amplification","Increased sensitivity or response","Preclinical stage","Stomach cancer","22729845, 23327903","116312443","116438440"],["overlap","3918","MET inhibitors","MET","Amplification","Increased sensitivity or response","Case report stage","Hepatocellular carcinoma","ENA 2015 (abstract A55)","116312443","116438440"],["overlap","2521","MetMab + erlotinib","MET","Increased MET expression","Increased sensitivity or response","Clinical trial stage","Lung cancer","http://meetinglibrary.asco.org/content/82156-102","Clinical trial stage","overlap","2521","MetMab + erlotinib","MET","Increased MET expression","Increased sensitivity or response","Clinical trial stage","Lung cancer","http://meetinglibrary.asco.org/content/82156-102","116312443","116438440"],["overlap","696","Onartuzumab","MET","AMPLIFICATION","Increased sensitivity or response","Case report stage","Gastric adenocarcinoma","22389872","116312459","116436396"],["overlap","4200","Trastuzumab in HER2-amplified","MET","Amplification","Reduced sensitivity or response","Clinical trial stage","Breast cancer","22850551","116312443","116438440"],["overlap","872","Vemurafenib","MET","OVEREXPRESSION","Reduced sensitivity or response","Clinical trial stage","Skin melanoma","26359985, 23802768","116312459","116436396"],["overlap","3573","Vemurafenib","MET","AMPLIFICATION","Increased sensitivity or response","Case report stage","Colorectal cancer","27325282","116312459","116436396"],["overlap","2595","Vemurafenib and panitumumab (in BRAF V600E mutated)","MET","Amplification","Reduced sensitivity or response","Case report stage","Colorectal cancer","27325282","116312443","116438440"]],"Protein":"p.G1108V"},"chr":"7","gene":"MET","transcript":"NM_001127500 (protein_coding)","end":"116417452","ref_allele":"G","start":"116417452"}]